Shin Nippon Biomedical Laboratories, EBIT

Shin Nippon Biomedical Laboratories, (2395.T) currently reports a EBIT of $4.3B as of June 2026. That compares with $6B in the prior-year period — down 28.6% year over year. That is below the sector sector average of $2.6T. Use the charts on this page to explore Shin Nippon Biomedical Laboratories,'s EBIT history and peer comparisons.

Shin Nippon Biomedical Laboratories,'s EBIT decreased from $6B to $4.3B — a 28.6% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Shin Nippon Biomedical Laboratories,'s EBIT of $4.3B is lower than the its sector sector average of $2.6T. That is roughly 99.8% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Shin Nippon Biomedical Laboratories, reported $4.3B in EBIT as of June 2026. That compares with $6B in the prior-year period — down 28.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $4.3B, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $2.6T. From there, open related valuation or income-statement pages for Shin Nippon Biomedical Laboratories,, and consider following 2395.T for alerts when major investors trade the stock.